The largely consolidated vendor landscape of the global unfractionated heparin market features several large international companies and a handful of well-established local players operating in promising regional markets, states Transparency Market Research in a recent report. To gain a larger control on the market, companies are putting more emphasis on strategic collaborations and expansion in lucrative untapped regional markets. Focus on regional markets such as Asia Pacific and Latin America has thus significantly increased.
Some of the leading companies in the market are Sagent Pharmaceuticals, Pfizer, Inc., Fresenius SE & Co. KGaA, B. Braun Melsungen AG, LEO Pharma A/S, and Baxter International Inc.The report states that the market will exhibit a promising 6.4% CAGR over the period between 2017 and 2025, rising from a valuation of US$955.9 mn in 2016 to a revenue opportunity of US$1664.4 mn in 2025.
Porcine-based Unfractionated Heparin Serves Maximum Demand
Unfractionated heparin is chiefly manufactured from bovine- and porcine-based sources. Of these, the segment of porcine based heparin accounted for the dominant share in the global market in terms of demand served and revenue contributed. This can be mainly attributed to the large-scale ban on the use of bovine-based unfractionated heparin in Europe and the U.S. for the past many years.From a geographical standpoint, the market for unfractionated heparin in North America accounted for the dominant share in the overall market in 2016, mainly owing to the high prevalence of conditions associated with coagulation such as deep vein thrombosis and pulmonary embolism.